zepbound tirzepatide eli lilly manufacturer to sell directly to consumers without insurance coverage Eli Lilly to sell Zepbound – FDA approval for Zepbound (tirzepatide)

Yes, multiple clinical trials have shown reductions in heart attack, stroke, and cardiovascular death in high-risk patients

doi: 10.1038/s41586-020-2222-z 108 NajmAMassonFMPreussPGeorgesSOryBQuillardTet al

After the study, it was observed that both the peptides appeared to have the potential to restore basic bodily functions in geriatric subjects including improved functions in the cardiovascular, endocrinal, immune, and nervous systems, along with normalized metabolic and hemostatic activities

Initial improvements in autoimmune markers may appear within 68 weeks, with hair regrowth following over 36 months depending on the severity and duration of the condition